Surgery in Addition to the Medical Treatment of Lymphedema (LYMPHOSPIR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03776214|
Recruitment Status : Recruiting
First Posted : December 14, 2018
Last Update Posted : December 18, 2018
Lymphedema is a chronic pathology with a real impact on the quality of life of patients. Despite optimal medical management of patients, some patients still have no pitting edema on which the medical treatment has no effect.
It is adipose tissue secondary to the evolution of lymphedema. It is often painful and important in terms of volume with the resulting functional consequences. The investigators propose to these patients a surgical management complementary to the optimal medical treatment by microlipoaspiration associated or not with a dermolipectomy. This surgical management began in 2014 in our service. The investigators want to evaluate the impact on quality of life of patients in this surgical management in addition to medical care.
|Condition or disease|
|Optimal Treatment of Lymphedema|
This is a monocentric, observational cohort study.
Main judgment criteria:
Evolution of the quality of life score of the LYMQOL self-questionnaire between preoperative and postoperative (at 3.6 and 12 months) The investigators used a French translation of Keeley's LYMQOL (Quality Of Life Measure for Limb Lymphoedema) self-administered questionnaire in 2010 (2) to assess the quality of life of patients. This is a lymphedema specific questionnaire for which there is one version for the upper limb and one for the lower limb. Limb function, lymphedema symptoms, body image and mood are assessed independently. It allows to obtain a score between 1 and 4 which corresponds to the discomfort felt. The higher the score, the better the quality of life. It also includes, in the last question, a numerical scale allowing the patient to note her quality of life between 0 and 10.
Since 2016, patients have systematically completed quality of life questionnaires. Perimeter measurements are also done systematically at each visit, these data are available in the patient's computerized medical records (Dx Care).
Secondary judgment criterion:
Difference in the volume of the limb operated between preoperative and postoperative (3, 6 and 12 months)
The volume is calculated on the basis of stepped circumferential measurements (every 10 cm starting from the patella for the lower limb and every 5 cm starting from the bend of the elbow for the upper limb). These measures are taken at each consultation by our physiotherapists, specialized nurses or vascular doctors.
It is therefore a question of retrospectively analyzing the data collected.
The data will then be anonymised by a two-letter code and a number and will be entered on a Excel file available on a secure directory of the CHU for analysis.
A dedicated support protocol is already implemented in the Cf Appendix service. There are no special modalities for patients not included in the study.
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||LYMPHOSPIR : Impact of Surgery in Addition to Optimal Management of Lymphedema.|
|Actual Study Start Date :||April 1, 2018|
|Estimated Primary Completion Date :||December 31, 2019|
|Estimated Study Completion Date :||December 31, 2019|
- quality of life (self questionnaire LYMQOL) [ Time Frame: 1 day ]To evaluate the impact of surgery in addition to the medical management of lymphedema on the quality of life of operated patients between preoperative and postoperative
- volume of operated limb [ Time Frame: 1 day ]Evaluate the effectiveness of surgery in addition to medical management in terms of volume reduction of the operated limb between preoperative and postoperative.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03776214
|Contact: MESTRE GODIN Sandrine, MD, PhD||467337028 ext email@example.com|
|Contact: VALDELIEVRE Emilie, MD||467337028 ext firstname.lastname@example.org|
|Montpellier, France, 34295|
|Contact: MESTRE GODIN Sandrine 467337028 ext 33 email@example.com|
|Principal Investigator:||MESTRE GODIN Sandrine||University Hospital, Montpellier|